The invention can be used for the prevention and treatment of tuberculosis. Hybrid proteins including immunogenic fragments of proteins Ag85B, Tb10.4 M. tuberculosis, FliC S.Typhimurium, connected by flexible bridges, encoding polynucleotides, genetic constructs for expression of polynucleotides, producers and variants of the vaccine for the prevention and treatment of tuberculosis. The consumer of the developed vaccine is a person, or an animal. The proposed vaccine has an efficacy greater than that of BCG.
The vaccine provides safety and simplicity in production and application.
The invention received prizes at international exhibitions of inventions and innovative technologies «Archimedes» and «New time»